Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability

Overview

Journal Neoplasia

Publisher Elsevier

Specialty Oncology

Date 2019 Mar 10

PMID 30851646

Citations 19

Authors

Monika Raab

Mourad Sanhaji

Shengtao Zhou

Franz Rodel

Ahmed El-Balat

Sven Becker

Klaus Strebhardt

Affiliations

Soon will be listed here.

Abstract

Paclitaxel is a frontline drug for the treatment of epithelial ovarian cancer (EOC). However, following paclitaxel-platinum based chemotherapy, tumor recurrence occurs in most ovarian cancer patients. Chromosomal instability (CIN) is a hallmark of cancer and represents genetic variation fueling tumor adaptation to cytotoxic effects of anticancer drugs. In this study, our Kaplan-Meier analysis including 263 ovarian cancer patients (stages I/II) revealed that high Polo-like kinase (PLK) 1 expression correlates with bad prognosis. To evaluate the role of PLK1 as potential cancer target within a combinatorial trial, we induced strong mitotic arrest in ovarian cancer cell lines by synergistically co-targeting microtubules (paclitaxel) and PLK1 (BI6727) followed by pharmaceutical inhibition of the Anaphase-Promoting Complex (APC/C) using proTAME. In short- and long-term experiments, this triple treatment strongly activated apoptosis in cell lines and primary ovarian cells derived from cancer patients. Mechanistically, BI6727/paclitaxel/proTAME stabilize Cyclin B1 and trigger mitotic arrest, which initiates mitochondrial apoptosis by inactivation of antiapoptotic BCL-2 family proteins, followed by activation of caspase-dependent effector pathways. This triple treatment prevented endoreduplication and reduced CIN, two mechanisms that are associated with aggressive tumors and the acquisition of drug resistance. This "two-punch strategy" (strong mitotic arrest followed by blocking mitotic exit) has important implications for developing paclitaxel-based combinatorial treatments in ovarian cancer.

Citing Articles

Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options.

Nunes M, Bartosch C, Abreu M, Richardson A, Almeida R, Ricardo S Cells. 2024; 13(9.

PMID: 38727322 PMC: 11083313. DOI: 10.3390/cells13090786.

S-72, a Novel Orally Available Tubulin Inhibitor, Overcomes Paclitaxel Resistance via Inactivation of the STING Pathway in Breast Cancer.

Hou Z, Lin S, Du T, Wang M, Wang W, You S Pharmaceuticals (Basel). 2023; 16(5).

PMID: 37242532 PMC: 10221130. DOI: 10.3390/ph16050749.

Chromosomal Instability as Enabling Feature and Central Hallmark of Breast Cancer.

Castellanos G, Valbuena D, Perez E, Villegas V, Rondon-Lagos M Breast Cancer (Dove Med Press). 2023; 15:189-211.

PMID: 36923397 PMC: 10010144. DOI: 10.2147/BCTT.S383759.

Targeting the anaphase-promoting complex/cyclosome (APC/C) enhanced antiproliferative and apoptotic response in bladder cancer.

Sevim Nalkiran H, Akcora Yildiz D, Saydam F, Guzel A, Nalkiran I Saudi J Biol Sci. 2023; 30(3):103564.

PMID: 36794046 PMC: 9923226. DOI: 10.1016/j.sjbs.2023.103564.

Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification.

Gasimli K, Raab M, Tahmasbi Rad M, Kurunci-Csacsko E, Becker S, Strebhardt K Int J Mol Sci. 2022; 23(18).

PMID: 36142803 PMC: 9502276. DOI: 10.3390/ijms231810892.

References

Strebhardt K, Kneisel L, Linhart C, Bernd A, Kaufmann R . Prognostic value of pololike kinase expression in melanomas. JAMA. 2000; 283(4):479-80. DOI: 10.1001/jama.283.4.479. View

Knecht R, Oberhauser C, Strebhardt K . PLK (polo-like kinase), a new prognostic marker for oropharyngeal carcinomas. Int J Cancer. 2000; 89(6):535-6. View

Duesberg P, Stindl R, Hehlmann R . Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassortments that are catalyzed by aneuploidy. Proc Natl Acad Sci U S A. 2000; 97(26):14295-300. PMC: 18912. DOI: 10.1073/pnas.97.26.14295. View

Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R, Miyakawa I . Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage. Cancer Lett. 2001; 164(1):41-9. DOI: 10.1016/s0304-3835(00)00703-5. View

Wolf G, Hildenbrand R, SCHWAR C, Grobholz R, Kaufmann M, STUTTE H . Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer. Pathol Res Pract. 2001; 196(11):753-9. DOI: 10.1016/S0344-0338(00)80107-7. View

Duesberg P, Stindl R, Hehlmann R . Origin of multidrug resistance in cells with and without multidrug resistance genes: chromosome reassortments catalyzed by aneuploidy. Proc Natl Acad Sci U S A. 2001; 98(20):11283-8. PMC: 58721. DOI: 10.1073/pnas.201398998. View

Spankuch-Schmitt B, Wolf G, Solbach C, Loibl S, Knecht R, Stegmuller M . Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene. 2002; 21(20):3162-71. DOI: 10.1038/sj.onc.1205412. View

Trimbos J, Vergote I, Bolis G, Vermorken J, Mangioni C, Madronal C . Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst. 2003; 95(2):113-25. View

Colombo N, Guthrie D, Chiari S, Parmar M, Qian W, Swart A . International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst. 2003; 95(2):125-32. DOI: 10.1093/jnci/95.2.125. View

10.

Takahashi T, Sano B, Nagata T, Kato H, Sugiyama Y, Kunieda K . Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci. 2003; 94(2):148-52. PMC: 11160284. DOI: 10.1111/j.1349-7006.2003.tb01411.x. View

11.

Liu X, Erikson R . Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci U S A. 2003; 100(10):5789-94. PMC: 156279. DOI: 10.1073/pnas.1031523100. View

12.

Ozols R, Bundy B, Greer B, Fowler J, Clarke-Pearson D, Burger R . Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003; 21(17):3194-200. DOI: 10.1200/JCO.2003.02.153. View

13.

du Bois A, Luck H, Meier W, Adams H, Mobus V, Costa S . A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003; 95(17):1320-9. DOI: 10.1093/jnci/djg036. View

14.

Liu X, Erikson R . Polo-like kinase 1 in the life and death of cancer cells. Cell Cycle. 2003; 2(5):424-5. View

15.

Weichert W, Denkert C, Schmidt M, Gekeler V, Wolf G, Kobel M . Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer. 2004; 90(4):815-21. PMC: 2410182. DOI: 10.1038/sj.bjc.6601610. View

16.

Spankuch B, Matthess Y, Knecht R, Zimmer B, Kaufmann M, Strebhardt K . Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst. 2004; 96(11):862-72. DOI: 10.1093/jnci/djh146. View

17.

Yamada S, Ohira M, Horie H, Ando K, Takayasu H, Suzuki Y . Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas. Oncogene. 2004; 23(35):5901-11. DOI: 10.1038/sj.onc.1207782. View

18.

Rieder C, Maiato H . Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell. 2004; 7(5):637-51. DOI: 10.1016/j.devcel.2004.09.002. View

19.

Vasey P, Jayson G, Gordon A, Gabra H, Coleman R, Atkinson R . Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004; 96(22):1682-91. DOI: 10.1093/jnci/djh323. View

20.

Montero A, Fossella F, Hortobagyi G, Valero V . Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol. 2005; 6(4):229-39. DOI: 10.1016/S1470-2045(05)70094-2. View